STAT December 26, 2019
For biotech, 2019 ended like the penultimate episode of a prestige TV show. We got answers to some weighty questions, but mostly, the year left a breadcrumb trail to some major reveals.
The IPO window stayed open, helping scores of companies go public. Futuristic therapies proved their worth in clinical trials, pointing to a new era in medicine. And the markets ended the year on a high, buoyed by a Food and Drug Administration that seems ever more flexible when it comes to approving new drugs.
Now, with 2020, we’ll get the more important answers. Sure, there’s a lot of public biotech companies now, but what if that’s a bad thing? Yes, cell and gene therapies look transformational, but what...
Today's Sponsors
Today's Sponsor